Adam P. Westhorpe

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Repurposed small molecule toxin inhibitors neutralise a diversity of venoms from the Neotropical viperid snake genus Bothrops.

Repurposed small molecule toxin inhibitors neutralise a diversity of venoms from the Neotropical viperid snake genus Bothrops.

Journal: eLife
Published: July 31, 2026

Identification of DC-174 as a Novel Hydroxamic Precandidate for the Development of an Oral Snakebite Treatment.

Identification of DC-174 as a Novel Hydroxamic Precandidate for the Development of an Oral Snakebite Treatment.

Journal: Journal of medicinal chemistry
Published: April 09, 2026

Snake Venom Metalloproteinases from Puff Adder and Saw-Scaled Viper Venoms Cause Cytotoxic Effects in Human Keratinocytes.

Snake Venom Metalloproteinases from Puff Adder and Saw-Scaled Viper Venoms Cause Cytotoxic Effects in Human Keratinocytes.

Journal: Toxins
Published: December 16, 2024

Molecular dissection of cobra venom highlights heparinoids as an antidote for spitting cobra envenoming.

Molecular dissection of cobra venom highlights heparinoids as an antidote for spitting cobra envenoming.

Journal: Science translational medicine
Published: July 17, 2024

Intraspecific venom variation in the medically important puff adder (Bitis arietans): Comparative venom gland transcriptomics, in vitro venom activity and immunological recognition by antivenom.

Intraspecific venom variation in the medically important puff adder (Bitis arietans): Comparative venom gland transcriptomics, in vitro venom activity and immunological recognition by antivenom.

Journal: PLoS neglected tropical diseases
Published: June 26, 2024

Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults.

Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults.

Journal: EBioMedicine
Published: May 16, 2024

Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform.

Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform.

Journal: Frontiers in pharmacology
Published: October 31, 2023

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors.

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors.

Journal: Frontiers in pharmacology
Published: October 27, 2023

Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms.

Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms.

Journal: Nature communications
Published: May 24, 2022

Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing.

Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing.

Journal: PLoS neglected tropical diseases
Published: May 16, 2022

In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus.

In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus.

Journal: Toxicon: X
Published: December 29, 2021
Showing 1-11 of 11

Last Updated: 09/26/2026